» Articles » PMID: 38678096

Gastrointestinal Bleeding in Elderly Patients with Atrial Fibrillation: Prespecified All Nippon Atrial Fibrillation in the Elderly (ANAFIE) Registry Subgroup Analysis

Abstract

Gastrointestinal (GI) bleeding control is critical in elderly patients with atrial fibrillation (AF) receiving oral anticoagulants (OAC). This subgroup analysis aimed to clarify the actual state and significance of GI bleeding in elderly non-valvular AF (NVAF) patients. We evaluated the incidence and risk factors of GI bleeding during the 2-year follow-up and examined the GI bleeding impact on mortality. Of the 32,275 patients in the ANAFIE Registry, 1139 patients (3.5%) experienced GI bleeding (incidence rate, 1.92 events per 100 person-years; mean follow-up, 1.88 years); 339 upper and 760 lower GI bleeding events occurred. GI bleeding risk factors included age ≥ 85 years, body mass index ≥ 25.0 kg/m, prior major bleeding, hyperuricaemia, heart failure, P-glycoprotein inhibitor use, GI disease, and polypharmacy (≥ 5 drugs). No significant differences in GI bleeding risk were found between direct OAC (DOAC) vs warfarin users (adjusted hazard ratios [95% confidence interval], 1.01 [0.88-1.15]). The 1-year post-GI bleeding mortality rate was numerically higher in patients with upper (19.6%) than lower GI bleeding (8.9%). In elderly Japanese NVAF patients, this large-scale study found no significant difference in GI bleeding risk between DOAC vs. warfarin users or 1-year mortality after upper or lower GI bleeding.

Citing Articles

Time in the therapeutic range, bleeding event, and their determinants in older patients with atrial fibrillation on warfarin in Ethiopia: multicenter cross-sectional study.

Addisu Z, Demsie D, Tafere C, Yazie T, Endeshaw D, Tefera B Front Pharmacol. 2025; 16:1541592.

PMID: 40017601 PMC: 11864910. DOI: 10.3389/fphar.2025.1541592.


Gastrointestinal bleed mortality disparities in patients with atrial fibrillation: A cross-sectional analysis 1999-2020.

Sainbayar E, Ibrahim R, Noh S, Pham H, Shahid M, Elias J J Arrhythm. 2025; 41(1):e13223.

PMID: 39817013 PMC: 11730723. DOI: 10.1002/joa3.13223.


Characteristics of Gastrointestinal Bleeding While Taking Direct Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation and Differences Among Drugs-A Single-Center Retrospective Cohort Study.

Aoki N, Abe K, Tokutomi H, Kajita K, Sone M, Honda T J Clin Med. 2025; 14(1.

PMID: 39797177 PMC: 11722488. DOI: 10.3390/jcm14010095.

References
1.
Steinberg B, Simon D, Thomas L, Ansell J, Fonarow G, Gersh B . Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial.... Am J Cardiol. 2017; 119(10):1590-1595. DOI: 10.1016/j.amjcard.2017.02.015. View

2.
Sato H, Ishikawa K, Kitabatake A, Ogawa S, Maruyama Y, Yokota Y . Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke. 2005; 37(2):447-51. DOI: 10.1161/01.STR.0000198839.61112.ee. View

3.
Goodman S, Wojdyla D, Piccini J, White H, Paolini J, Nessel C . Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol. 2013; 63(9):891-900. PMC: 4206565. DOI: 10.1016/j.jacc.2013.11.013. View

4.
Verso M, Giustozzi M, Vinci A, Franco L, Vedovati M, Marchesini E . Risk factors and one-year mortality in patients with direct oral anticoagulant-associated gastrointestinal bleeding. Thromb Res. 2021; 208:138-144. DOI: 10.1016/j.thromres.2021.10.022. View

5.
Bai Y, Deng H, Shantsila A, Lip G . Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation: Systematic Review and Meta-Analysis. Stroke. 2017; 48(4):970-976. DOI: 10.1161/STROKEAHA.116.016275. View